Metformin promotes susceptibility to experimental Leishmania braziliensis infection
Mem. Inst. Oswaldo Cruz
; 115: e200272, 2020. graf
Article
de En
| LILACS, SES-SP
| ID: biblio-1135255
Bibliothèque responsable:
BR1.1
ABSTRACT
BACKGROUND Metformin (MET) is a hypoglycemic drug used for the treatment of diabetes, despite interference in host immunity against microorganisms. Cutaneous infection caused by pathogens such as Leishmania braziliensis (Lb), the agent responsible for cutaneous leishmaniasis (CL) in Brazil, represents an interesting model in which to evaluate the effects associated with MET. OBJECTIVE To evaluate the modulatory effect of MET in Lb infection. MATERIAL AND METHODS Experimental study of Lb infection and MET treatment in BALB/c mice and Raw 264.7 macrophages. FINDINGS MET treatment interfered with lesion kinetics, increased parasite load and reduced macrophage proliferation. Low concentrations of MET in Lb culture allow for the maintenance of stationary parasite growth phase. Lb-infected cells treated with MET exhibited increased parasite load. While both MET and Lb infection alone promoted the production of intracellular reactive oxygen species (ROS), reduced levels of ROS were seen in MET-treated Lb-infected macrophages. MAIN CONCLUSION Experimental treatment with MET interfered with the kinetics of cutaneous ulceration, increased Lb parasite load, altered ROS production and modulated cellular proliferation. Our experimental results indicate that MET interfere with the evolution of CL.
Mots clés
Texte intégral:
1
Indice:
LILACS
Sujet Principal:
Leishmaniose cutanée
/
Leishmania
/
Metformine
Type d'étude:
Prognostic_studies
Limites du sujet:
Animals
Pays comme sujet:
America do sul
/
Brasil
langue:
En
Texte intégral:
Mem. Inst. Oswaldo Cruz
Thème du journal:
MEDICINA TROPICAL
/
PARASITOLOGIA
Année:
2020
Type:
Article